Where to buy tirzepatide.

You can buy tirzepatide from a pharmacy on prescription, as Mounjaro or Zepbound, from a 503A compounding pharmacy in narrowing circumstances, or from a research-supply vendor as lab powder. Those are the three legal channels for tirzepatide for research and for treatment in 2026, and they aren't interchangeable.

Tirzepatide

Referenced in this guide

Batch-matched COAHPLC + mass specResearch use only

The Tirzepatide referenced throughout this article, supplied as a research compound with a certificate of analysis matched to the lot you receive — the check this site argues you should hold any supplier to.

Shop Tirzepatide

Where can you buy tirzepatide?

You can buy tirzepatide in three places: a retail pharmacy on prescription, a 503A compounding pharmacy, or a research-supply vendor. We built this side-by-side so you can rule out two of them in a minute.

• Prescription Mounjaro or Zepbound. The FDA-approved finished drug, made by Eli Lilly. Needs a prescription. About $1,060/month cash, less with insurance. For human therapeutic use.
• 503A compounded tirzepatide. A pharmacy mixes injectable tirzepatide for a named patient with a prescription. $300–$600/month. Legal channel narrowed sharply in October 2024.
• third-party tested tirzepatide. Freeze-dried powder sold as a laboratory reference compound. No prescription. Not for human use. $140–$280 per 10 mg vial.

Same molecule across all three. Different supply chains, different rules, different intended uses. We'll walk through each in plain English below.

What is tirzepatide, and what does it do?

Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist at the GIP and GLP-1 receptors. Studies have looked at its effects on insulin secretion, gastric emptying and energy balance.

The SURMOUNT-1 trial ran in 2,539 people. Participants on tirzepatide 15 mg once weekly showed a 22.5% mean reduction in body weight at 72 weeks, against 2.4% on placebo, Jastreboff and colleagues reported.

SURPASS-2 put it head to head with semaglutide in 1,879 people with type 2 diabetes. Tirzepatide 15 mg produced a 2.30-point HbA1c reduction and an 11.2 kg body weight reduction, beating semaglutide on both.

Channel 1: Mounjaro or Zepbound by prescription

A prescription is the only legal way to get tirzepatide for human use. Mounjaro was approved for type 2 diabetes on May 13, 2022. Zepbound was approved for chronic weight management on November 8, 2023. Same molecule in both, with a different label and a different indication.

Key channel characteristics:

• Access route. Via a licensed prescriber (primary care, endocrinologist, or telehealth provider). Cash price is roughly $1,060 per month. With insurance, copays frequently range from $25–$100.
• Product form. A pre-filled single-dose injection pen at 2.5, 5, 7.5, 10, 12.5, or 15 mg. Sterile, injection-ready, dispensed with the FDA-approved prescribing information.
• Regulatory status. The only channel approved for human therapeutic use. Requires a valid prescription and documented clinical indication.
• Coverage note. Insurance coverage for the weight management indication varies substantially. Out-of-pocket Zepbound at $12,000+/year is a reported cost for cash-pay patients.

Channel 2: 503A compounded tirzepatide

Compounded tirzepatide is the channel that's changed most in the last year, and the change went against you. Here's what happened.

A 503A compounding pharmacy is a licensed pharmacy that mixes drugs from raw ingredients to fill an individual prescription. Think of it as bespoke pharmacy work, regulated under Section 503A of the federal drug law.

During the 2022–2024 supply crunch, the FDA put tirzepatide on its Drug Shortage list. That listing authorized 503A pharmacies to compound their own tirzepatide for patients who couldn't get the branded product.

Key channel characteristics:

• Access route. A licensed prescriber writes a prescription; a 503A pharmacy compounds and ships. Cost runs $300–$600 per month.
• Product form. Compounded injectable tirzepatide vials, often available in custom concentrations not offered in the branded pens.
• Legal reality in 2026. Post-delisting, the legitimate compounding window is narrow. Vendors still operating on the shortage rationale are outside FDA guidance. The primary risk is supply-chain disruption.
• Quality considerations. 503A pharmacies do not operate under the same cGMP standard as Eli Lilly. Sterility testing on the finished injectable varies by pharmacy.

Channel 3: research-grade tirzepatide

Research-grade tirzepatide is the channel the rest of this guide covers, and we want to be straight about what it is and isn't.

It's the same 39-residue peptide as Mounjaro's active ingredient, ordered from a peptide synthesis house and sold as freeze-dried powder. It carries a Research Use Only label and is meant for laboratory work. It isn't a drug product, and it isn't for human use.

Key channel characteristics:

• Access route. Order from a research-supply company. No prescription required. Ships as lyophilized powder in a sealed research vial.
• Pricing benchmarks. $140–$280 per 10 mg vial. The 20 mg size runs $260–$520. Bulk discounts of 10–25% are common on 3-packs and 6-packs.
• Documentation. A Certificate of Analysis (CoA) from an independent laboratory, confirming HPLC purity at ≥98% plus mass-spec identity, ships with every lot.
• Regulatory framing. Labeled Research Use Only; not for human or veterinary administration.

Which channel-3 vendors to shortlist

Six vendors inside channel 3, ordered the way our supplier comparison orders them — on what each one will show you rather than what it claims — with every column pulled from the vendor's own storefront on 13 August 2026; there is no verified tirzepatide price anywhere in that set, so pricing is benchmarked on BPC-157 across the same vendors and no price column appears here.

† Limitless Biotech gates every price behind an account, so nothing it sells can be compared until you have registered. This table covers channel 3 only — if what you want is treatment, channels 1 and 2 above are the answer and none of these rows applies to you. Stock varies by compound, so confirm a vendor lists tirzepatide before you compare; what these columns describe is disclosure practice, and that is the part that travels across every compound a vendor sells. Disclosure: this site earns a commission on purchases made through its links, and Peptriva is one of the vendors it links to. Every column above is a document you can open or a page you can load yourself.

Several vendors list tirzepatide under a codename rather than the compound name, and a codename is not an identity check. The identity check is CAS 2023788-19-2 on the certificate's identity line together with an observed intact mass from the vendor's own mass-spec trace — require both on the document before you accept that a codenamed listing is this molecule.

How do the three tirzepatide channels compare?

Here's the tirzepatide comparison if you're still deciding, across cost, prescription status, human use, oversight, flexibility and reliability.

• Cost benchmarks. Prescription Zepbound: ~$1,060 cash/month. 503A compounded: $300–$600/month. third-party tested: roughly $140–$280 per 10 mg vial.
• Prescription required. Channels 1 and 2: yes. Channel 3: no.
• Appropriate for human administration. Channel 1: yes, it's FDA-approved. Channel 2: yes, within narrowing legal parameters. Channel 3: no, it's Research Use Only.
• Quality oversight. Channel 1: FDA cGMP, full pharma quality system. Channel 2: state board of pharmacy plus 503A rules. Channel 3: third-party CoA, no FDA oversight on the final powder.
• Concentration flexibility. Channel 1: six fixed-dose pens per the approved label. Channel 2: custom concentrations available at the compounding pharmacy's discretion. Channel 3: researcher-controlled reconstitution volume.
• Supply reliability in 2026. Channel 1: excellent. Channel 2: variable, enforcement actions ongoing. Channel 3: stable from credible vendors.

How do you verify tirzepatide before you buy?

Four checks separate a credible tirzepatide supplier from a sketchy one. The compound must be named rather than coded. The mass-spec must read about 4813 Da. The price must sit above the semaglutide-substitution line. And stability data must exist. Our general peptide buyer's guide has the longer version.

1. The product page says "tirzepatide," not a codename

Some grey-market vendors sell what they call tirzepatide under opaque labels like FG2-T or FG-blend, refusing to confirm chemical identity. The pattern is usually about dodging Eli Lilly's patent enforcement. But it also lets vendors swap the actual contents of the vial without you knowing.

Our rule: if it's not labeled tirzepatide on both the product page and the CoA, it isn't tirzepatide. You're buying an unknown compound.

2. Mass-spec on the CoA shows ~4813 Da

Tirzepatide's full molecular weight, with the lipid side chain attached, is about 4813 Da. A CoA that reports an observed mass near 4813 Da confirms the molecule is what the label says.

A CoA showing a mass near 4114 Da? That's semaglutide, not tirzepatide. The 700-Da gap is impossible to miss on a competent mass spectrometer. If the mass-spec line is missing entirely, you can't rule out substitution.

3. The semaglutide substitution risk is real

Semaglutide costs roughly 30% as much to make as tirzepatide. Tirzepatide has 8 more amino acids and a more complex lipid modification.

So when a vendor lists tirzepatide at $60 per 10 mg vial, there's a strong chance you're actually paying tirzepatide prices for semaglutide. This isn't theoretical. We've seen it happen.

4. Storage and stability data exist

Tirzepatide's lipid chain makes the molecule more sensitive to freeze-thaw than simpler peptides. A credible supplier publishes how long the powder stays stable at −20 °C and how long a reconstituted solution lasts at refrigerator temperature. Vendors that ship a vial with no stability documentation are skipping a step that matters.

What does tirzepatide cost in 2026?

Research-grade tirzepatide costs $140–$280 per 10 mg vial in 2026, against $300–$600 a month compounded and about $1,060 a month for prescription Zepbound. Here's where each research size should sit.

• 5 mg vial: $80–$150 ($16–$30 per mg).
• 10 mg vial: $140–$280 ($14–$28 per mg). The most common retail size.
• 20 mg vial: $260–$520, with a small per-mg discount.
• 3-pack or 6-pack: 10–25% off per vial at most reputable suppliers.

Below $100 per 10 mg vial, pause. The synthesis floor for a 39-residue lipid-modified peptide is real. Manufacturing cost runs roughly 10x that of a simpler 15-residue peptide like BPC-157. A supplier offering $60 per 10 mg is doing one of four things:

• Running at a loss to win new customers (it happens, but rarely).
• Shipping a lower-purity preparation.
• Substituting semaglutide under a tirzepatide label.
• Selling something else entirely.

The mass-spec CoA tells you which one. That's why we keep coming back to it.

What are the red flags when buying tirzepatide?

Seven things would make us walk away from a tirzepatide listing. The first two, a codename and a missing mass line, mean you can't know what's in the vial at all.

• Sold under codenames (FG2-T, FG-blend). The single biggest tirzepatide red flag.
• Price below $100 per 10 mg vial. Below the synthesis cost floor. Ask why.
• No mass-spec on the CoA, or a mass near 4114 Da. That's semaglutide. Walk away.
• Human dosing instructions on the product page. Directions to self-administer at weekly doses, usually copied straight off the Zepbound titration schedule, mean the vendor is marketing for human use. That sits outside FDA guidance for a research supplier.
• No third-party lab partner. Internal-only QC isn't enough for a molecule this complex. ISO/IEC 17025 accredited testing is the standard.
• "Same as Mounjaro" or "pharmaceutical-grade" copy. That blurs a research compound into a prescription drug, and the FDA notices.
• No lot numbers, or recycled CoAs. Each batch should have its own lot and its own CoA.

Tirzepatide

10 mg ≥99% pure Lyophilized

39-residue GIP/GLP-1 dual agonist with C20 fatty-diacid acyl modification. Lot-specific CoA with ISO/IEC 17025 third-party HPLC and mass-spec identity ships with every order, including the modified-peptide mass-spec line that distinguishes tirzepatide from semaglutide.

Learn more

Frequently asked questions

Is third-party tested tirzepatide the same molecule as Mounjaro?

Chemically, yes. Both are the same 39-amino-acid peptide with the same lipid side chain, CAS 2023788-19-2. What differs is the regulatory framing, the supply chain and the intended use.

Mounjaro and Zepbound are FDA-approved finished drugs, made by Eli Lilly under cGMP and dispensed by a pharmacy on your prescription. Research tirzepatide is laboratory powder, labeled Research Use Only, not for human use.

Can tirzepatide be obtained from a telehealth provider?

Yes. Tirzepatide is FDA-approved, and telehealth providers routinely prescribe it when you meet the clinical criteria. That's Channel 1 in this guide, the prescription pathway for human therapeutic use.

Research tirzepatide sold as a reference compound is a separate channel, and it isn't for human administration.

Why is research-grade tirzepatide cheaper than compounded?

Three reasons:

• Compounded tirzepatide carries pharmacy preparation costs, sterility testing, prescriber consultation, and pharmacy markup.
• Research material ships as bulk powder, without the prescription or finished-form costs.
• The legal compounding window narrowed in October 2024 when the FDA delisted tirzepatide from the Drug Shortage list, reducing supply on the 503A side.

Is research-grade tirzepatide legal in the USA?

Yes, when labeled and sold as Research Use Only. FDA-approved drug molecules can be sold as analytical reference standards for laboratory work, under the same framework governing other research reference compounds.

Selling tirzepatide as a therapeutic without a prescription is illegal. Purchasing it from a supplier that labels and ships it as RUO for laboratory research purposes is legal. Intended use must remain consistent with the research framing.

How do I know my tirzepatide isn't actually semaglutide?

Mass spectrometry. Tirzepatide's observed mass should be near 4813 Da. Semaglutide is near 4114 Da. A CoA showing the right mass confirms the molecule. A CoA missing that line, or showing 4114 Da, tells you what's actually in the vial.

What does tirzepatide cost compared to Zepbound?

Three tiers:

• Zepbound cash price: ~$1,060/month.
• 503A compounded: $300–$600/month.
• third-party tested: $140–$280 per 10 mg vial.

The tiers aren't directly comparable as cost-per-dose. They reflect different supply chains, regulatory frameworks, and intended uses.

How does tirzepatide compare to retatrutide?

Tirzepatide is the approved dual-receptor benchmark with the largest Phase III evidence base behind it. Retatrutide adds a third receptor target, and its Phase II data reported 24.2% mean body weight reduction.

But retatrutide is still pre-approval and available only as a research reference compound. Our retatrutide vs. tirzepatide article has the full breakdown.